Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,079.45 +1.70 (+0.16%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

AlphaFold’s Five-Year Reign: 3 Million Researchers and the Dawn of a New Biological Era

Today 15:14 EST

In a milestone that cements artificial intelligence as the most potent tool in modern science, Google DeepMind’s AlphaFold has officially surpassed 3 million users worldwide. This achievement coincides...

Via TokenRing AI

Topics Artificial Intelligence Climate Change

The 2026 Horizon: Wall Street Bets on the 'Application Era' and the Nuclear Renaissance

Today 14:35 EST

As the final trading days of 2025 come to a close, Wall Street is pivoting its focus from the hardware-driven "AI Gold Rush" toward a 2026 outlook defined by practical utility, autonomous software, and...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

The Great Rebalancing: Investors Pivot Away from Big Tech as 2026 Looms

Today 14:22 EST

As the final trading days of 2025 wind down, a massive tactical shift is sweeping through Wall Street. Institutional fund managers and retail investors alike are aggressively rebalancing portfolios,...

Via MarketMinute

Topics Artificial Intelligence Bonds ETFs

The Great Pivot: Navigating the Rollercoaster 2025 Market as the Final Bell Approaches

Today 10:22 EST

As the sun sets on December 29, 2025, the U.S. stock market stands at a historic crossroads, capping off a year defined by extreme volatility, political brinkmanship, and a definitive shift in monetary...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

S&P 500 Tests Resilience: Technical Pullback Follows Historic Record Highs as 2025 Draws to a Close

Today 10:20 EST

The S&P 500 (NYSE:SPY) entered the final week of 2025 in uncharted territory, having notched a series of historic closing records that culminated in a Christmas Eve milestone. However, as the calendar...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance

Today 10:19 EST

As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of...

Via PredictStreet

Topics Earnings Economy Intellectual Property

This Beaten-Down Stock Just Jumped By 8%. Time to Buy? ↗

Today 9:05 EST

Is this the start of a sustained run for the Danish drugmaker?

Via The Motley Fool

Eli Lilly & Co (NYSE:LLY) Stands Out as a Secure Dividend Growth Stock ↗

Today 8:01 EST

Eli Lilly (LLY) offers a secure, growing dividend supported by strong profitability and financial health, ideal for a dividend growth investment strategy.

Via Chartmill

Novo Nordisk Slashes Weight Loss Drug Price By Up To 50% In China: Report ↗

Today 7:14 EST

Prices of Wegovy’s two highest doses were reduced to 987.48 yuan ($141) and 1,284.36 yuan, according to a Bloomberg article on Monday, citing Yicai.

Via Stocktwits

Topics Intellectual Property

The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. ↗

Today 4:43 EST

Other drugmakers seem to be too far behind to disrupt this duopoly, at least for now.

Via The Motley Fool

1 Stock Under $50 on Our Buy List and 2 We Find Risky

December 28, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

Topics Economy

Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ)

December 28, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Drug Stocks to Buy at a Discount ↗

December 27, 2025

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Via The Motley Fool

Topics Intellectual Property

The Best Stocks to Invest $50,000 in Right Now ↗

December 27, 2025

If you're investing for the long run, there are a myriad of companies begging to be bought.

Via The Motley Fool

Topics Artificial Intelligence

Here Are My Top 3 Growth Stocks to Buy Now ↗

December 27, 2025

These profitable businesses have plenty of room left to run.

Via The Motley Fool

Should You Invest in Ozempic Maker Novo Nordisk in 2026? ↗

December 26, 2025

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Via The Motley Fool

Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026 ↗

December 26, 2025

Via MarketBeat

The Ghost Town Effect: How Thin Holiday Liquidity is Jolting US Equities

December 26, 2025

The halls of the New York Stock Exchange are quiet as the final week of 2025 unfolds, but the price tickers are anything but calm. Following the Christmas holiday, the U.S. stock market has entered its...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Sector Rotation: 2 Smart Money Moves for 2026 ↗

December 26, 2025

Via MarketBeat

This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling ↗

December 26, 2025

The FDA is expected to issue a decision on Vanda’s Tradipitant, a motion-sickness treatment aimed at preventing vomiting, on Dec. 30, 2025.

Via Stocktwits

Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree ↗

December 26, 2025

A key product portfolio is bringing in blockbuster revenue.

Via The Motley Fool

The Biological Turing Point: How AlphaFold 3 and the Nobel Prize Redefined the Future of Medicine

December 25, 2025

In the final weeks of 2025, the scientific community is reflecting on a year where the boundary between computer science and biology effectively vanished. The catalyst for this transformation was...

Via TokenRing AI

Topics Artificial Intelligence Initial Public Offering

The Great Broadening: How AI Implementation Reshaped the Non-Tech Bottom Line in 2025

December 25, 2025

As the curtain closes on 2025, the narrative that dominated Wall Street for the past three years has undergone a fundamental transformation. What began as a speculative frenzy centered around silicon...

Via MarketMinute

Topics Artificial Intelligence Economy Fraud

Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle? ↗

December 25, 2025

It's a two-horse race right now, sort of.

Via The Motley Fool

Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom

December 25, 2025

NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of...

Via MarketMinute

Topics Economy Intellectual Property

The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill

December 25, 2025

Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the...

Via PredictStreet

Topics Economy Intellectual Property World Trade

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

December 25, 2025

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...

Via PredictStreet

Topics Artificial Intelligence Economy Intellectual Property

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

December 25, 2025

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...

Via PredictStreet

Topics Economy Government Intellectual Property

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

December 25, 2025

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Via Barchart.com

Topics Workforce

Eli Lilly & Co (NYSE:LLY) Presents a Compelling Growth at a Reasonable Price (GARP) Case ↗

December 25, 2025

Eli Lilly (LLY) exemplifies Growth at a Reasonable Price (GARP) with top-tier earnings, strong expansion, and a valuation balanced against its industry-leading growth outlook.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.